TradeFlare's AI research teams analysed ACRS on 6 market nights between May 26, 2026 and August 26, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 26, 2026 | BUY | $6.53 | $7.84 / $5.55 | -0.2% | -13.1% | The setup is a 52-week breakout with strong fundamental and sentiment support, suggesting potential for sustained upward momentum over a few weeks. |
| July 30, 2026 | BUY | $5.12 | — / — | +14.5% | +15.8% | Pipeline advancements and analyst upgrades are driving positive news flow. |
| July 1, 2026 | BUY | $5.29 | — / — | +6.9% | -0.4% | Continued positive news flow regarding ACRS's clinical pipeline development. |
| June 2, 2026 | BUY | $4.34 | — / — | -7.1% | +15.3% | The current market regime and the stock's fundamental and technical profiles do not support a buy recommendation. |
| May 27, 2026 | BUY | $4.51 | — / — | -3.5% | +7.2% | The current market and stock setup does not warrant a trade. |
| May 26, 2026 | BUY | $4.52 | — / — | +2.7% | +6.2% | The current market regime and stock-specific factors do not present a clear, high-conviction trading opportunity. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.